Providers

Latest News

VTCE might be useful to identify portal hypertension beyond splenomegaly in patients with BCR::ABL1-negative MPN. | Image credit:| Dr_Microbe - stock.adobe.com
Spleen Stiffness Measurement Linked With Portal Hypertension in MPNs

June 7th 2025

A new report suggests a noninvasive means to evaluate portal hypertension in patients with BCR::ABL1-negative myeloproliferative neoplasms.

The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com
Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

June 7th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma.  | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Providers reported issues with accessing diagnostic tests, such as laboratory and lung function tests, and limited availability of pulmonary rehabilitation and home oxygen for rural patients. | Image credit: BJP7images - stock.adobe.com
Patients With ILD in Rural Areas Face Barriers to Care

June 7th 2025

The findings show that ctDNA is worthy of additional study as a tool for assessing risk and treatment response in large B-cell lymphoma, the authors concluded. | Image credit: Connect world - stock.adobe.com
Biomarker-Adapted Treatment Effective in High-Risk LBCL

June 7th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo